CVAC: CureVac Pharma Cash Funds per Share

Symbol and logo of brand CureVac N.V. (CVAC)

This cash per share chart demonstrates the liquidity of CureVac N.V. (CVAC), which adheres to ESG standards and bioethics in the development of mRNA drugs. The 2.18 mark characterizes this parameter, given that pricing policy depends on grants from strategic partners. The business specifics are non-cyclical, as demand for innovative vaccines is dictated exclusively by scientific achievements and epidemiology.

CureVac Corp (CVAC): Cash per Share from 07/04/2022 to 01/17/2026

Analytical breakdowns for CureVac N.V.

- market price and analyst price targets:
- market capitalization information:
- cash and cash flow data:
General company analysis:CureVac N.V.
Flagship merchandise of CureVac NV

CureVac N.V. (CVAC) incurs high costs to maintain ultra-low temperatures during the delivery of mRNA drugs, requiring a significant liquid reserve to ensure supply chain continuity. Calculating this metric by dividing total cash holdings by the number of shares allows for an assessment of the business's internal resilience, making cash per share a key indicator of the company's solvency and survival during periods of macroeconomic instability.